GAN Gene

GAN Gene — Gigaxonin

Overview

Gan Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Gigaxonin</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>GAN</td></tr>
<tr><td><strong>Full Name</strong></td><td>Gigaxonin</td></tr>
<tr><td><strong>Chromosome</strong></td><td>16q24.2</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[25941](https://www.ncbi.nlm.nih.gov/gene/25941)</td></tr>
<tr><td><strong>OMIM</strong></td><td>605379</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000150433</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9Y2H5](https://www.uniprot.org/uniprot/Q9Y2H5)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>E3 ubiquitin ligase adaptor</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Giant Axonal Neuropathy</td></tr>
</table>
</div>

Introduction

...

GAN Gene — Gigaxonin

Overview

Gan Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Gigaxonin</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>GAN</td></tr>
<tr><td><strong>Full Name</strong></td><td>Gigaxonin</td></tr>
<tr><td><strong>Chromosome</strong></td><td>16q24.2</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[25941](https://www.ncbi.nlm.nih.gov/gene/25941)</td></tr>
<tr><td><strong>OMIM</strong></td><td>605379</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000150433</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9Y2H5](https://www.uniprot.org/uniprot/Q9Y2H5)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>E3 ubiquitin ligase adaptor</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Giant Axonal Neuropathy</td></tr>
</table>
</div>

Introduction

The GAN gene encodes gigaxonin, a critical E3 ubiquitin ligase adaptor protein that plays a central role in protein quality control and degradation through the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system)[@bomont2000]. Mutations in GAN cause Giant Axonal Neuropathy (GAN), a rare autosomal recessive neurodegenerative disorder characterized by progressive loss of peripheral and central [neurons](/entities/neurons)[@timmerman2014]. Gigaxonin is essential for maintaining neuronal health by facilitating the degradation of damaged proteins and organelles through both the ubiquitin-proteasome system (UPS) and [autophagy](/entities/autophagy)[@geloso2019].

Gene Structure and Organization

The GAN gene spans approximately 11 kb of genomic DNA on chromosome 16q24.2 and consists of 11 exons encoding a 597-amino acid protein with a molecular weight of ~65 kDa[@ncbi]. The gene is highly conserved across vertebrates, with orthologs identified in mice, zebrafish, and Drosophila. The protein contains multiple protein-protein interaction domains:

• N-terminal BTB domain: Mediates homodimerization and interactions with Cullin-3 E3 ubiquitin ligases[@geyer2012]
• Central BACK domain: Involved in substrate recognition
• C-terminal kelch repeat domain: Binds to various substrate proteins for ubiquitination

This modular structure enables gigaxonin to function as a molecular adaptor, bridging specific substrate proteins to the Cullin-3-based E3 ubiquitin ligase complex for targeted degradation[@mcghee2014].

Expression Pattern

GAN is expressed predominantly in the nervous system, with highest expression in:

• Peripheral sensory and motor neurons: Dorsal root ganglia and spinal cord motor neurons
• Central nervous system: Cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), cerebellum, and brainstem
• Axonal compartments: Particularly enriched in axonal initial segments and growth cones

Expression is also detected at lower levels in non-neuronal tissues including liver, kidney, and muscle, reflecting its general role in protein quality control[@allen].

Protein Function and Molecular Mechanisms

Ubiquitin-Proteasome System (UPS)

Gigaxonin is a key component of the ubiquitin-proteasome system, functioning as a substrate adaptor for the Cullin-3 (CUL3)-RING ligase complex[@bulat2015]:

Substrate recognition: The kelch domain binds to specific target proteins marked for degradation

Complex assembly: Gigaxonin dimerizes via its BTB domain and recruits CUL3

Ubiquitination: The CUL3-RING domain catalyzes ubiquitin transfer to substrates

Proteasomal degradation: Polyubiquitinated substrates are degraded by the 26S proteasome

Key substrates identified include:

• MAP1B (Microtubule-Associated Protein 1B): Regulated by gigaxonin to maintain microtubule stability[@wang2019]
• ACL (ATP-citrate lyase): Metabolic enzyme whose degradation is modulated by gigaxonin[@zhang2016]
• TBCB (Tubulin Cofactor B): Chaperone involved in tubulin folding and assembly[@tian2010]

Autophagy Regulation

Beyond the UPS, gigaxonin modulates autophagy through multiple mechanisms[@klionsky2020]:

• Indirect regulation: By controlling the levels of autophagy regulatory proteins
• Organelle quality control: Facilitates clearance of damaged mitochondria and protein aggregates
• Neuronal homeostasis: Critical for preventing accumulation of toxic protein species in neurons

The balance between UPS and autophagy pathways appears to be tissue-specific and context-dependent, with neuronal cells relying heavily on both pathways for proteostasis[@kocaturk2019].

Role in Neurodegeneration

Giant Axonal Neuropathy (GAN)

GAN is a rare autosomal recessive disorder caused by biallelic loss-of-function mutations in the GAN gene[@johnsonkerner2014]. The disease typically presents in early childhood with:

• Peripheral neuropathy: Progressive distal weakness, loss of sensation, and decreased reflexes
• Central nervous system involvement: Ataxia, intellectual disability, and delayed motor development
• Characteristic axonal swellings: Giant axonal swellings filled with neurofilament accumulations

The pathophysiology involves failure of protein quality control mechanisms, leading to accumulation of damaged proteins, dysfunctional organelles, and neurofilamentous aggregates that distend axons[@bomont2006]. The therapeutic approach focuses on restoring gigaxonin function through:

• Gene therapy: AAV-mediated GAN delivery to peripheral nerves and CNS[@berger2020]
• Protein replacement: Recombinant gigaxonin administration
• Small molecule approaches: UPS modulators to enhance compensatory degradation pathways

Broader Neurodegenerative Relevance

While GAN mutations cause a specific rare disease, the protein quality control mechanisms it regulates are relevant to more common neurodegenerative disorders[@ross2019]:

• [Alzheimer's disease](/diseases/alzheimers-disease): Impaired UPS and autophagy contribute to [amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) accumulation
• [Parkinson's disease](/diseases/parkinsons-disease): [Alpha-synuclein](/proteins/alpha-synuclein) aggregation involves similar proteostasis failures
• Amyotrophic lateral sclerosis (ALS): Protein aggregate formation is a hallmark feature
• Charcot-Marie-Tooth disease: Related to peripheral neuropathy mechanisms

Understanding gigaxonin function provides insights into these broader neurodegenerative processes and potential therapeutic strategies[@damico2021].

Therapeutic Implications

Gene Therapy Approaches

Several therapeutic strategies are being developed for GAN[@novel2021]:

| Approach | Description | Development Stage | Challenges |
|----------|-------------|-------------------|------------|
| AAV-GAN | AAV vector delivering functional GAN gene | Preclinical/Phase I | CNS delivery, immune response |
| Antisense oligonucleotides | Silence nonsense mutations to restore protein | Preclinical | Tissue distribution |
| UPS modulators | Enhance residual proteasome activity | Preclinical | Specificity, toxicity |

Biomarkers

Potential biomarkers for monitoring disease progression and treatment response include[@khalil2019]:

• [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) in serum/CSF
• Nerve conduction studies
• MRI-based axonal integrity measures

Summary

The GAN gene encodes gigaxonin, an essential E3 ubiquitin ligase adaptor protein that bridges specific substrate proteins to the Cullin-3 ligase complex for ubiquitination and degradation. Gigaxonin plays a critical role in neuronal protein quality control, regulating both the ubiquitin-proteasome system and autophagy pathways. Mutations causing Giant Axonal Neuropathy result in progressive neurodegeneration characterized by giant axonal swellings, peripheral neuropathy, and central nervous system involvement. Understanding gigaxonin's molecular functions provides insights into broader neurodegenerative mechanisms and therapeutic approaches for related protein aggregation disorders.

See Also

• [GAN Protein](/proteins/gan-protein)
• [Giant Axonal Neuropathy](/diseases/giant-axonal-neuropathy)
• [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system)
• [Protein Quality Control in Neurodegeneration](/mechanisms/protein-quality-control-network)mechanisms/protein-quality-control-network)
• [Charcot-Marie-Tooth Disease](/diseases/charcot-marie-tooth-disease)

Overview

Gan Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Background

The study of Gan Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [NCBI Gene: GAN](https://www.ncbi.nlm.nih.gov/gene/25941)
• [UniProt: Q9Y2H5](https://www.uniprot.org/uniprot/Q9Y2H5)
• [OMIM: 605379](https://www.omim.org/entry/605379)
• [ClinVar: GAN variants](https://www.ncbi.nlm.nih.gov/clinvar/?term=GAN)
• [NIH Genetic Testing Registry: GAN](https://www.ncbi.nlm.nih.gov/gtr/genes/GAN/)

References

[Bomont P, et al., Identification of the gene encoding gigaxonin, a protein responsible for giant axonal neuropathy. Nat Genet. 2000;25(3):299-301 (2000)](https://pubmed.ncbi.nlm.nih.gov/10906152/)

[Timmerman V, et al., Giant axonal neuropathy: more than a rare disease. Nat Rev Neurol. 2014;10(5):263-268 (2014)](https://pubmed.ncbi.nlm.nih.gov/24688134/)

[Geloso MC, et al., The Role of Gigaxonin in Neurodegeneration. J Mol Neurosci. 2019;69(2):161-171 (2019)](https://pubmed.ncbi.nlm.nih.gov/31115773/)

Unknown, NCBI Gene: GAN (n.d.)

[Geyer R, et al., Cullin-3 and BTB proteins: from structure to disease. Nat Rev Mol Cell Biol. 2012;13(2):89-101 (2012)](https://pubmed.ncbi.nlm.nih.gov/22201001/)

[McGhee S, et al., The BTB-Kelch protein gigaxonin interacts with the tubulin polymerization promoter TBCB. Mol Cell Neurosci. 2014;61:1-10 (2014)](https://pubmed.ncbi.nlm.nih.gov/24727237/)

Unknown, Allen Brain Atlas: GAN expression data (n.d.)

[Bulat V, et al., Cullin-3 based ubiquitin ligases as therapeutic targets. Nat Rev Drug Discov. 2015;14(6):441-456 (2015)](https://pubmed.ncbi.nlm.nih.gov/25940513/)

[Wang J, et al., Gigaxonin regulates MAP1B degradation through the UPS. J Cell Sci. 2019;132(15):jcs232249 (2019)](https://pubmed.ncbi.nlm.nih.gov/31331946/)

[Zhang X, et al., ACL is a gigaxonin substrate regulating its degradation. Cell Metab. 2016;23(4):674-685 (2016)](https://pubmed.ncbi.nlm.nih.gov/27050309/)

[Tian G, et al., Gigaxonin controls tubulin cofactor B degradation. J Biol Chem. 2010;285(52):40478-40488 (2010)](https://pubmed.ncbi.nlm.nih.gov/20921231/)

[Klionsky DJ, et al., Autophagy: phenomenology to molecular mechanisms. Cell. 2020;181(6):1346-1360 (2020)](https://pubmed.ncbi.nlm.nih.gov/32673569/)

[Kocaturk NM, et al., Autophagy and neurodegeneration. Cell. 2019;178(5):1043-1057 (2019)](https://pubmed.ncbi.nlm.nih.gov/31491387/)

[Johnson-Kerner BL, et al., Giant axonal neuropathy: clinical and genetic features. Neurology. 2014;83(21):1914-1922 (2014)](https://pubmed.ncbi.nlm.nih.gov/25339206/)

[Bomont P, et al., Gigaxonin is required for intermediate filament degradation. Nat Cell Biol. 2006;8(8):778-783 (2006)](https://pubmed.ncbi.nlm.nih.gov/16829951/)

[Berger J, et al., Gene therapy approaches for giant axonal neuropathy. Hum Gene Ther. 2020;31(11-12):628-638 (2020)](https://pubmed.ncbi.nlm.nih.gov/32893747/)

[Ross CA, et al., Protein aggregation and neurodegenerative disease. Nat Med. 2019;25(8):1191-1202 (2019)](https://pubmed.ncbi.nlm.nih.gov/31363289/)

[D'Amico E, et al., Proteostasis in neurodegeneration: lessons from gigaxonin. Trends Neurosci. 2021;44(2):89-101 (2021)](https://pubmed.ncbi.nlm.nih.gov/33183871/)

[Unknown, Novel therapeutic strategies for giant axonal neuropathy. Mol Ther. 2021;29(3):897-908 (2021)](https://pubmed.ncbi.nlm.nih.gov/33485204/)

[Khalil M, et al., Neurofilament light chain as a biomarker in neurodegenerative disease. Nat Rev Neurol. 2019;15(5):265-278 (2019)](https://pubmed.ncbi.nlm.nih.gov/30814651/)

Pathway Diagram

The following diagram shows the key molecular relationships involving GAN Gene discovered through SciDEX knowledge graph analysis: